Loading publications…
The last 5 uploaded publications
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
Mees Egeler, Julia Lai‐Kwon, Renaud Tissier, Itske Fraterman, Anke Kuijpers, Winan J. van Houdt, Sofie Wilgenhof, Aparna D. Rao, Shahneen Sandhu, Rebecca Lee, Hanna Eriksson, Marieke van Leeuwen, Kelly de Ligt, Alexander C.J. van Akkooi, Lonneke V. van de Poll‐Franse (2024). Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy. , 200, DOI: https://doi.org/10.1016/j.ejca.2024.113601.
Article63 days agoHealth-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy
Jake Thompson, Julia Lai‐Kwon, Rachael L. Morton, Alexander Guminski, Maria Gonzalez, Victoria Atkinson, Shahneen Sandhu, Michael P. Brown, Alexander M. Menzies, Grant A. McArthur, Serigne Lo, Georgina V. Long, Iris Bartula (2023). Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy. , 15(8), DOI: https://doi.org/10.2217/imt-2022-0262.
Article63 days agoImpact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review
Julia Lai‐Kwon, Andrisha–Jade Inderjeeth, Karolina Lisy, Shahneen Sandhu, Claudia Rutherford, Michael Jefford (2023). Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review. , 184, DOI: https://doi.org/10.1016/j.ejca.2023.02.005.
Article63 days agoImpact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review
Julia Lai‐Kwon, Andrisha–Jade Inderjeeth, Karolina Lisy, Shahneen Sandhu, Claudia Rutherford, Michael Jefford (2023). Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review. , 184, DOI: https://doi.org/10.1016/j.ejca.2023.02.005.
Article63 days agoEvolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling
David D.L. Bowtell, Heather Thorne, Kathryn Alsop, Stephen Cordner, Noel Woodford, Jodie Leditschke, Patricia J. O’Brien, Sarah‐Jane Dawson, Grant A. McArthur, Graham J. Mann, Mitchell P. Levesque, Anthony T. Papenfuss, Mark Shackleton, Ismael A. Vergara, Christopher Mintoff, Shahneen Sandhu, Lachlan McIntosh, Richard J. Young, Stephen Q. Wong, Andrew J. Colebatch, Daniel Cameron, Julia Lai‐Kwon, Rory Wolfe, Angela Peng, Jason Ellul, Xuelin Dou, Clare G. Fedele, Samantha Boyle, Gisela Mir Arnau, Jeanette Raleigh, Athena Hatzimihalis, Pacman Szeto, Jennifer Mooi, Daniel Widmer, Phil F. Cheng, Valerie C. Amann, Reinhard Dummer, Nicholas K. Hayward, James S. Wilmott, Richard A. Scolyer, Raymond J. Cho (2021). Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. , 12(1), DOI: https://doi.org/10.1038/s41467-021-21576-8.
Article63 days ago